Drugs / CBX-250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06994676 | Jul 2025 → Jan 2027 expected | acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Crossbow Therapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-16 | Crossbow Therapeutics, Inc. | Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies crossbowtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBX-250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06994676 ↗ |
| Route | Subcutaneous | “CBX-250 will be administered subcutaneously in 28-day cycles” NCT06994676 ↗ |